tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
US Market
RARE
Ultragenyx Pharmaceutical
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Advertisement

Ultragenyx Pharmaceutical (RARE) Stock News & Sentiment

Compare
1,016 Followers
Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
Premium
Ratings
Ultragenyx Pharmaceutical: Promising Phase 3 Results for DTX401 Reinforce Buy Rating
10d ago
RARE
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
Premium
Ratings
Ultragenyx Pharmaceuticals: Strong Buy Rating Backed by Promising Osteogenesis Imperfecta Program and Strategic Developments
11d ago
RARE
Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
Premium
Ratings
Ultragenyx’s DTX401: Promising Phase 3 Results and Commercial Viability Support Buy Rating
12d ago
RARE
Buy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy
Premium
Ratings
Buy Rating Affirmed for Ultragenyx Pharmaceutical: Promising Phase III Results of DTX401 Gene Therapy
12d ago
RARE
Ultragenyx Reports Positive Phase 3 Gene Therapy Results
Premium
Company Announcements
Ultragenyx Reports Positive Phase 3 Gene Therapy Results
13d ago
8K
RARE
Ultragenyx’s Strategic Progress with DTX401 Gene Therapy Drives Buy Rating Amid Promising Market Potential
Premium
Ratings
Ultragenyx’s Strategic Progress with DTX401 Gene Therapy Drives Buy Rating Amid Promising Market Potential
1M ago
RARE
Ultragenyx Pharmaceutical: Promising Developments and Strategic Advancements Support Buy Rating
Premium
Ratings
Ultragenyx Pharmaceutical: Promising Developments and Strategic Advancements Support Buy Rating
1M ago
RARE
More RARE News >

RARE News on the Web

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
Zacks
Neutral
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
Zacks
Bullish
Ultragenyx Reports Positive Phase 3 Gene Therapy Results
TipRanks News
Neutral
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Zacks
Neutral
Why Ultragenyx Pharmaceutical Inc.’s (RARE) Stock Is Down 5.72%
AAII
Neutral
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks
Neutral
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Zacks
Neutral
Piper Sandler Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
TipRanks News
Neutral

News Score - Last 7 Days

Neutral
RARE
Sector Average
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
This Week50%
Sector Average57%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is RARE’s Media Buzz Sentiment?
Currently, no data Available
What is RARE’s weekly average amount of articles?
Currently, no data Available
What is RARE’s News Sentiment?
50% of articles about RARE were positive this week, compared to its sector average of 57%.
    Healthcare Stocks that are Trending in the News
    GLUEMonte Rosa Therapeutics
    LHLabcorp Holdings
    OCCOrthocell Ltd
    GEHCGE Healthcare Technologies Inc
    BDXBecton Dickinson
    Showing the stocks with the most bullish news sentiment over the past week

    Become an Expert with TipRanks Premium

    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis
    Subscribe NowSee Plans & Pricing